Insights
Insights From Our Experts
Articles
Most Favored Nation Pricing | Insights and Implications for Manufacturers
The EVERSANA MANAGEMENT CONSULTING team provides an overview of the recent developments and shares their views on the strategic implications for manufacturers. Manufacturers must act decisively to mitigate Most Favored Nation (MFN) exposure through global pricing…
Demystifying Market Access: A Must-Read for Navigating the Lab-to-Patient Journey
Market access is no longer just a final hurdle—it’s a strategic imperative that shapes how therapies reach the patients who need them most. If you’ve ever wondered what it really takes to bring a treatment from…
Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In a recent EVERSANA webinar, experts Maneesh Gupta, Jennifer Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key challenges: 3x lower…
EVERSANA Returns as Global Host and Presenting Sponsor for Frontiers Health 2025
Building on its commitment to global health innovation and bringing innovators together from around the globe, EVERSANA returns as the Global Host and Presenting Sponsor of Frontiers Health 2025, which will take place November 11-12 in…
Staying Ahead of the Curve in Pharmacovigilance: CIOMS XIV Draft “Artificial Intelligence in Pharmacovigilance”
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…
Staying Ahead of the Curve in Pharmacovigilance: Outcome of GVP Inspections by NPRA
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…
From Science to Value: Strategic Asset Valuation for Biotech Licensing and Fundraising
Early-stage biotech companies face a critical challenge: transforming promising science into compelling commercial value. Investors and partners fund future potential, not mechanisms—especially when data is limited and market entry is years away. This white paper, authored…
Trends Shaping Direct-to-Patient in Pharma – Insights from Scott Snyder
The latest wave of artificial intelligence (AI), digital health, and Direct-to-Patient (DTP) models have the potential to drive significant innovation, transform patient experiences, and redefine business and operating models across life science companies. Estimates show that…
Celebrating Excellence: Two EVERSANA Leaders Named 2025 PM360 ELITE 100 Winners
Posted by
on May 9, 20255/9/25
PM360 has announced its 2026 ELITE 100 winners, and two EVERSANA team members are on the list. Daniel Pfeffer, Senior Manager, Data Science, has been recognized in the Data Miner category, and Katie Beller, SVP,…
Staying Ahead of the Curve in Pharmacovigilance: Emerging Regulations and Their Implications in Saudi Arabia
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…